CCL17-neutralizing and esterase-responsive core-shell microgels for endogenous Tregs recruitment and functional enhancement in myocardial infarction Authors: Liang Song, Yongyuan Kang, Pai Peng, Qiaoxuan Wang, Shuqin Wang, Liyin Shen, Jinyue Zhang, Yang Zhu, Changyou Gao Published: 2026 ABSTRACT Myocardial infarction (MI) disrupts immune homeostasis by impairing the recruitment and suppressive function of regulatory T cells (Tregs), which are hard to restore to date. In this study, a dual-functional platform based on core-shell microgels (Ab/HAPA C-S MGs) was developed to enhance Tregs homing and function within the post-infarct environment. The surface-modified C-C motif chemokine ligand 17 (CCL17) antibody neutralized excess CCL17, thereby enabling targeted Tregs recruitment. Propionic acid (PA) was released via hydrolytic cleavage of an encapsulated prodrug precursor (HAPA) within the core to promote Tregs immunosuppressive activity through fatty acid oxidation. The platform ensured localized retention and release of PA, addressing the pharmacokinetic limitations characteristic of short-chain fatty acid (SCFAs). The Ab/HAPA@C-S MGs enhanced Tregs recruitment by 4.2-fold through CCL17 neutralization, while enzymatically released PA boosted Tregs immunosuppression with 1.8-fold higher Foxp3 expression in vitro. In MI models, treatment with Ab/HAPA@C-S MGs promoted a 2.4-fold increase in Tregs infiltration while reducing Th17 cells in infarcted region, ultimately improving cardiac functions and attenuating myocardial fibrosis. These findings show potential of the SCFA-based C-S MGs system on regulating the immunomodulation and cardiac tissue repair. Introduction Myocardial infarction (MI) triggers an acute immune response to clear necrotic tissue [[1], [2], [3]]. However, persistent inflammation often leads to immune dysregulation, fibrosis, and adverse remodeling, resulting in heart failure [[4], [5], [6]]. It is significant and challenging to restore the immune homeostasis post-MI [7,8]. Regulatory T cells (Tregs) are a specialized subset of cluster of differentiation 4-positive (CD4+) T cells that play an important role in maintaining immune balance and preventing excessive immune responses [9,10]. Their immunosuppressive function relies heavily on the stable expression of the transcription factor Forkhead/winged helix transcription factor (Foxp3), which maintains Tregs functional integrity [[11], [12], [13]]. However, both the homing ability and immunosuppressive function of Tregs are compromised in the infarcted myocardium, limiting their immunomodulation function [[14], [15], [16], [17]]– (see Scheme 1).Scheme 1Design of Ab/HAPA@C-S MGs for coordinated CCL17 neutralization (shell) and PA release (core) to restore post-MI immune homeostasis. (a) Preparation of Ab/HAPA@C-S MGs via microfluidics. The core comprises HAPA, a prodrug polymer formed by covalently grafting propionic acid (PA) onto hyaluronic acid (HA), which allows for enzyme-responsive PA release. The shell is functionalized with a CCL17-neutralizing antibody (named as Ab) to restore Tregs recruitment. (b) Sequential immunomodulation strategy for post-MI therapy. The microgels promote Tregs recruitment by neutralizing CCL17 and enhance their immunosuppressive function through sustained PA-mediated epigenetic regulation. Additionally, PA facilitates macrophage polarization toward the reparative M2 phenotype, collectively contributing to immune homeostasis, improved cardiac function and reduced fibrosis. Design of Ab/HAPA@C-S MGs for coordinated CCL17 neutralization (shell) and PA release (core) to restore post-MI immune homeostasis. (a) Preparation of Ab/HAPA@C-S MGs via microfluidics. The core comprises HAPA, a prodrug polymer formed by covalently grafting propionic acid (PA) onto hyaluronic acid (HA), which allows for enzyme-responsive PA release. The shell is functionalized with a CCL17-neutralizing antibody (named as Ab) to restore Tregs recruitment. (b) Sequential immunomodulation strategy for post-MI therapy. The microgels promote Tregs recruitment by neutralizing CCL17 and enhance their immunosuppressive function through sustained PA-mediated epigenetic regulation. Additionally, PA facilitates macrophage polarization toward the reparative M2 phenotype, collectively contributing to immune homeostasis, improved cardiac function and reduced fibrosis. Recent studies have identified C-C motif chemokine ligand 17 (CCL17), a chemokine markedly upregulated post-MI, as a major factor impeding Tregs recruitment. CCL17 interacts with C-C chemokine receptor type 4 (CCR4) on Tregs but activates guanosine nucleotide-binding protein q subunit (Gq) signaling, which reduces the migration, disrupting their accumulation in the infarct zone [18,19]. To compensate for insufficient endogenous Tregs responses, adoptive Tregs therapy has been explored as a potential immunomodulatory strategy [[20], [21], [22]]. Recent advances in biomaterial-assisted delivery systems have enabled localized Tregs administration, which has been shown to improve cell retention, preserve immunosuppressive activity, and enhance therapeutic efficacy in inflammatory disease model [23,24]. These strategies highlight the feasibility of leveraging engineered delivery platforms to overcome the limitations of conventional systemic cell infusion. However, adoptive Tregs therapy still faces substantial translational barriers. The isolation, purification, and expansion of autologous Tregs ex vivo require specialized protocols and strict quality control, impeding large-scale standardized production and increasing manufacturing costs [25]. Moreover, systemically administered Tregs often suffer from poor survival and rapid functional attenuation within hostile inflammatory microenvironments [13]. The intrinsic instability and plasticity of Tregs also increase the risk of phenotypic drift and loss of suppressive function [26]. These findings highlight two major barriers to effective Treg-mediated immune regulation post MI: insufficient Tregs recruitment, and diminished Tregs function. Addressing both challenges simultaneously is essential for re-establishing immune homeostasis and facilitating tissue repair [13,23]. The immunomodulatory role of short-chain fatty acids (SCFAs) such as propionic acid (PA) has drawn increasing attention in Treg-based therapies [27,28]. SCFAs act as natural histone deacetylase (HDAC) inhibitors to enhance acetylation of key transcription factors such as Foxp3 and promote the production of anti-inflammatory cytokines such as interleukin-10 (IL-10). Through this epigenetic modulation, PA has been shown to stabilize Tregs and augment their suppressive function, contributing to immune regulation [[29], [30], [31], [32]]. In addition, PA influences innate immunity by promoting macrophage polarization toward the anti-inflammatory M2 phenotype, further supporting inflammation resolution and tissue repair [33,34]. However, due to their small molecular and rapid systemic clearance, SCFAs administered directly are unable to maintain effective concentration in the infarcted myocardium, limiting their ability to realize prolonged local immunomodulation and tissue repair. Herein, an immunomodulation strategy is designed to enhance Tregs recruitment and augment their immunosuppressive function simultaneously. A core-shell microgel platform (Ab/HAPA@C-S MGs) is designed and fabricated for CCL17 neutralization and localized delivery of PA. In this system, a CCL17-neutralizing antibody (named as Ab) is immobilized onto the microgel shell to restore Tregs recruitment within the infarcted myocardium. Concurrently, the microgel core is loaded with a PA prodrug (propionylated hyaluronic acid, HAPA), allowing for the sustained release of PA upon hydrolysis by esterase upregulated in the infarct microenvironment. In vitro studies were conducted to evaluate Tregs recruitment, Foxp3 expression, IL-10 secretion, and macrophage phenotypes, while in MI models were used to assess cardiac microenvironment and functions, thereby determining the therapeutic efficacy of the synergistic system. Results and discussion Preparation and characterization of Ab/HAPA@C-S MGs To overcome the rapid clearance and poor retention of small-molecule PA in myocardium, a prodrug HAPA was first synthesized (Fig. S1), and characterized through both nuclear magnetic resonance hydrogen spectroscopy (1H NMR) and Fourier transform infrared spectroscopy‌ (FTIR). Propionic anhydride reacts with the hydroxyl groups of hyaluronic acid (HA), enabling covalent grafting of PA onto the HA backbone. In the 1H NMR spectrum of HAPA (Fig. 1a), the characteristic peaks attributed to the methyl (-CH3) and methylene (-CH2-) protons of the grafted PA were observed at approximately 1.11 ppm and 2.45 ppm, respectively. Based on the integral ratio of these signals relative to the HA backbone protons, the degree of substitution was calculated to be approximately 1.36 per disaccharide unit, corresponding to a grafting efficiency of 34.0%. Complementarily, FTIR analysis revealed new absorption bands at 1730 cm−1, corresponding to the C=O stretching vibration of ester bonds, and at 1200-1300 cm−1 assigned to C-O stretching vibrations (Fig. 1b). These spectral changes further confirm the formation of ester.Fig. 1Synthesis and characterization of HAPA prodrug and HAPA@C-S MGs. (a) 1H NMR spectra of HAPA and HA. (b) FTIR spectra of HAPA and HA. (c) Scheme of the core-shell microgel (HAPA@C-S MGs) for sustained PA release (shell: HAMA; core: HAPA). (d-f) Bright-field (BF) and fluorescence microscopy (FM) images verifying the core-shell structure with FITC-labeled cores. (g,h) SEM images of freeze-dried HAPA@C-S MGs with different magnifications. (i) Analysis of rheological properties of the microgels. The storage modulus (G′) and loss modulus (G″) were measured over a frequency sweep (0-20 Hz). Synthesis and characterization of HAPA prodrug and HAPA@C-S MGs. (a) 1H NMR spectra of HAPA and HA. (b) FTIR spectra of HAPA and HA. (c) Scheme of the core-shell microgel (HAPA@C-S MGs) for sustained PA release (shell: HAMA; core: HAPA). (d-f) Bright-field (BF) and fluorescence microscopy (FM) images verifying the core-shell structure with FITC-labeled cores. (g,h) SEM images of freeze-dried HAPA@C-S MGs with different magnifications. (i) Analysis of rheological properties of the microgels. The storage modulus (G′) and loss modulus (G″) were measured over a frequency sweep (0-20 Hz). Next, a water-in-water-in-oil (W/W/O) emulsion was applied to prepare the core-shell microgels (HAPA@C-S MGs, Fig. 1c), where HAPA was encapsulated and immobilized within the inner core phase through the shell structure. Bright-field (BF) and fluorescence microscopy (FM) images (Fig. 1d) together clearly demonstrate the well-defined core-shell structure, with distinct boundaries between the core and shell. The resulting HAPA@C-S MGs exhibited an average total diameter of approximately 241 μm, a core diameter of 166 μm, and a shell thickness of 29 μm (Fig. S2a and b). Furthermore, scanning electron microscopy (SEM) analysis of freeze-dried microgels demonstrated preserved spherical morphology and structural integrity (Fig. 1g and h). Rheological characterization was performed to evaluate the viscoelastic properties of the microgels (Fig. 1i). Within the tested frequency range (0−20 Hz), the storage modulus (G′) was consistently higher than the loss modulus (G″), indicating dominant elastic behavior and the presence of a stable hydrogel network structure. Moreover, G’ remained relatively stable with a slight increase as frequency increased, suggesting weak frequency dependence and good structural integrity of the microgels under dynamic conditions. In addition, the swelling behavior of the microgels was characterized and showed an equilibrium swelling ratio of approximately 32% in phosphate-buffered saline (PBS) at 37 °C. MI often leads to excessive expression of the chemokine (C-C motif) ligand 17 (CCL17, also known as thymus and activation-regulated chemokine, TARC), which disrupts Tregs recruitment and delays the resolution of inflammation [19]. To counteract this effect, a functional surface modification was introduced to HAPA@C-S MGs to enable targeted neutralization of CCL17 and restore Tregs homing to the infarcted myocardium (Fig. 2a). First, a polydopamine (PDA) layer was deposited onto the microgel surface by incubating the HAPA@C-S MGs in a dopamine hydrochloride solution under pH 8.5, allowing for the spontaneous oxidative polymerization of dopamine (P@MGs). To prevent the detachment of biotin from the microgel surface, N-hydroxysuccinimide-biotin (NHS-biotin) was covalently conjugated to the P@MGs via an ethyldimethylaminopropyl carbodiimide (EDC)/NHS coupling reaction (PB@MGs). Streptavidin (SA) was then attached via the biotin-streptavidin interaction (PBSA@MGs), creating a stable platform for the subsequent grafting of biotinylated CCL17 antibodies (termed as Ab).Fig. 2Functional modification and characterization of Ab/HAPA@C-S MGs for targeted CCL17 neutralization and sustained PA release. (a) Schematic illustration of the multi-step surface modification process of HAPA@C-S MGs, including PDA coating (P@MGs), EDC/NHS-mediated biotinylation (PB@MGs), streptavidin (SA) immobilization (PBSA@MGs), and final conjugation with biotinylated anti-CCL17 antibodies (Ab) via biotin-streptavidin interactions (Ab/HAPA@C-S MGs). EDS mapping of C and N elements on HAPA@C-S MGs (b) before and (c) after PDA coating (P@MGs). (d) Wide scan XPS analysis of MGs and P@MGs. (e, f) High-resolution N 1s spectra of MGs and P@MGs. (g) Fluorescence microscopy of Cy3-SA labeled microgels (PBSA@MGs) after sequential surface modification with PDA and NHS-biotin. (h) ELISA for quantifying CCL17 neutralization capacity, showing the concentrations of unbound CCL17 in the supernatants. n ≥ 3. (i) Esterase-responsive PA release from free HAPA (100 IU/mL, 37 °C), and (j) magnified representation of (i) to better show the sustained PA release profile from HAPA@C-S MGs. Results are expressed as mean ± standard deviation (SD). n = 3. ####p < 0.0001 between the selected groups. Functional modification and characterization of Ab/HAPA@C-S MGs for targeted CCL17 neutralization and sustained PA release. (a) Schematic illustration of the multi-step surface modification process of HAPA@C-S MGs, including PDA coating (P@MGs), EDC/NHS-mediated biotinylation (PB@MGs), streptavidin (SA) immobilization (PBSA@MGs), and final conjugation with biotinylated anti-CCL17 antibodies (Ab) via biotin-streptavidin interactions (Ab/HAPA@C-S MGs). EDS mapping of C and N elements on HAPA@C-S MGs (b) before and (c) after PDA coating (P@MGs). (d) Wide scan XPS analysis of MGs and P@MGs. (e, f) High-resolution N 1s spectra of MGs and P@MGs. (g) Fluorescence microscopy of Cy3-SA labeled microgels (PBSA@MGs) after sequential surface modification with PDA and NHS-biotin. (h) ELISA for quantifying CCL17 neutralization capacity, showing the concentrations of unbound CCL17 in the supernatants. n ≥ 3. (i) Esterase-responsive PA release from free HAPA (100 IU/mL, 37 °C), and (j) magnified representation of (i) to better show the sustained PA release profile from HAPA@C-S MGs. Results are expressed as mean ± standard deviation (SD). n = 3. ####p < 0.0001 between the selected groups. The morphological and compositional changes during surface modification were systematically characterized. BF and SEM observations revealed clear differences before and after PDA coating. SEM results show that HAPA@C-S MGs exhibited a relatively rough and porous surface, while the P@MGs presented a smoother and denser morphology, indicative of the successful formation of a continuous PDA layer (Fig. S3a and b). In addition, the color of the microgels changed from white to brown under optical microscopy, further suggesting the deposition of PDA (Fig. S4a and b). Elemental analysis by energy dispersive X-ray spectroscopy (EDS) provided complementary evidence, showing the intense emergence of nitrogen (N) signals on the P@MGs (Fig. 2b and c). X-Ray photoelectron spectroscopy (XPS) analysis further verified the successful surface modification. The high-resolution spectra revealed C 1s, O 1s, and N 1s peaks in both samples, but with a noticeable increase in the nitrogen (N) atomic percentage from 5.4% in the pristine microgels to 8.3% after PDA coating, indicating N enrichment on the surface (Fig. 2d). In detail, the N 1s peak was centered at 399.8 eV, corresponding mainly to amine and amide nitrogen originating from the HA backbone in the pristine microgels. After PDA coating, the N 1s spectrum deconvoluted into three characteristic components assigned to pyridinic N (398.5 eV), pyrrolic N (400.0 eV), and oxidized N (401.8 eV) (Figs. S5a, b, Figure 2e, f), which are consistent with the typical N states in PDA networks [35]. To further confirm the successful biotin-streptavidin conjugation, Cy3-labeled streptavidin (Cy3-SA) was grafted onto two types of microgels: P@MGs and PB@MGs. Quantitative fluorescence measurement of the supernatant revealed a noticeable decrease in fluorescence intensity in both the P@MGs and PB@MGs (Fig. S6a). After rinsing with PBS, negligible residual fluorescence was observed on P@MGs under fluorescence microscopy. However, the PB@MGs showed much stronger fluorescence signals (Figure S6b, c and Fig. 2g). These results indicate that the nonspecifically adsorbed Cy3-SA was easily washed away and the remaining SA on the unmodified microgels was minimal, confirming that stable SA immobilization relied on the biotin-streptavidin interaction. The bioactivity of surface-immobilized CCL17 antibody was systematically assessed using a ligand neutralization assay. Specifically, Ab/HAPA@C-S MGs were co-incubated with recombinant CCL17 under physiological conditions, followed by quantitative analysis of unbound CCL17 in the supernatant via enzyme-linked immunosorbent assay (ELISA). Notably, ELISA quantification revealed a statistically significant decrease in soluble CCL17 level in the Ab/HAPA@C-S MG-treated group compared to Blank group, confirming both the preservation of antibody functionality post-conjugation and its specific binding capacity (Fig. 2h). Release of PA from HAPA@C-S MGs The PA release profiles from HAPA were characterized in vitro by mimicking the elevated esterase activity observed in the inflammatory microenvironment following MI [[36], [37], [38]]. Specifically, the enzymatic microenvironment was mimicked by supplementing the incubation medium with exogenous esterase (100 IU/mL). HAPA@C-S MGs were incubated in PBS containing esterase, while control groups consisted of HAPA in PBS with or without esterase for comparison. The degradation behavior and cumulative PA release were quantified using ultra performance liquid chromatography (UPLC). Results show that HAPA remained relatively stable in PBS, rapid degradation occurred in the presence of esterase, with a cumulative release of over 600 μg within 24 h, confirming the enzyme-responsiveness of the HAPA conjugate (Figure S7, Fig. 2i). Furthermore, sustainable and gradual release of PA from HAPA@C-S MGs was observed over time, with approximately 228 μg released within 24 h, suggesting the successful encapsulation and protection of HAPA within the microgel core (Fig. 2j). Tregs proliferation pattern and biocompatibility of Ab/HAPA@C-S MGs The survival and function of Tregs depend on exogenous interleukin-2 (IL-2) due to their high CD25 expression but limited endogenous IL-2 production [39,40]. In the absence of IL-2, Tregs remained quiescent and underwent apoptosis (Fig. S8a). Upon IL-2 stimulation, Tregs became activated and proliferate with a delayed onset, showing minimal expansion during the first two days followed by a linear growth phase from day 3 onward (Fig. S8b and c). The biocompatibility of both free HAPA and Ab/HAPA@C-S MGs was evaluated by exposing Tregs to different concentrations (0−15 mg/mL for HAPA; 0−75 mg/mL for extract of MGs). The results demonstrate negligible cytotoxicity, with Tregs viability remaining high across all the tested concentrations, indicating that Ab/HAPA@C-S MGs possessed good biosafety and were suitable for subsequent immunomodulatory applications (Fig. S9a). Importantly, HAPA exhibited comparable biocompatibility, showing no significant cytotoxicity even at the highest concentration (Fig. S9b). Enhancement of Tregs recruitment via CCL17 neutralization in vitro Due to their plasticity, Tregs are prone to dysfunction in inflammatory environments, where excessive CCL17 expression impairs their recruitment. To overcome this limitation, anti-CCL17 antibody was employed to locally neutralize CCL17 and restore a Tregs-permissive microenvironment. The potential of maintaining the immune homeostasis via Ab/HAPA@C-S MGs in the context of post-MI inflammation was assessed by two in vitro studies, focusing on the capacity to recruit Tregs and enhance their immunosuppressive function. The efficacy to recruit Tregs of this strategy was evaluated using a Transwell migration assay (Fig. 3a). Following a 3 h incubation at 37 °C, the migrated Tregs were quantified via flow cytometry. The chemokine (C-C motif) ligand 22 (CCL22)-treated group exhibited the highest efficiency in recruiting Tregs, highlighting the superior chemotactic capacity of CCL22 as a Tregs-specific chemoattractant. However, when CCL17 was added (Control group), the number of migrated Tregs was significantly reduced compared to the CCL22-only group. This result suggests that excessive CCL17 can impair Tregs chemotaxis even in the presence of favorable cue of CCL22, potentially due to competitive chemokine signaling or CCL17-induced phenotypic instability of Tregs [41]. In contrast, the number of migrated Tregs in the Ab/HAPA@C-S MGs group increased by approximately fourfold relative to the Control group (Fig. 3b and c) due to the effective neutralization of excess CCL17, thereby restoring the chemokine gradient and significantly improving the Tregs migration.Fig. 3Dual-modulation of Tregs recruitment and function via Ab/HAPA@C-S MGs through CCL17 neutralization and PA release. (a) Scheme of Transwell migration assay for Tregs recruitment assessment. Experimental groups included: 1) Blank: complete medium; 2) Control: 50 ng/mL CCL17 and 50 ng/mL CCL22; 3) CCL22: containing 50 ng/mL CCL22 alone as a positive control for Tregs recruitment; 4) HAPA@C-S MGs: 50 ng/mL CCL17 and 50 mg/mL HAPA@C-S MGs; 5) Ab/HAPA@C-S MGs: 50 ng/mL CCL17 and 50 mg/mL Ab/HAPA@C-S MGs. After 4 h incubation, migrated cells in the lower chamber were stained with anti-CD4 and anti-CD25 antibodies and analyzed by flow cytometry to quantify Tregs migration efficiency. (b, c) Flow cytometry analysis and quantification of migrated Tregs after 4 h incubation. (d) Schematic mechanism of PA's effects on Tregs function. Cells were stimulated with different conditioned media as follows. 1) Blank: without any additional treatment; 2) HA: HA solution; 3) SP: sodium propionate (2 mM), serving as a positive control to assess the effect of SCFA on Tregs; 4) HAPA@C-S MGs: Tregs cultured in PA-release medium obtained from HAPA@C-S MGs after esterase incubation. (e, f) Flow cytometry of Tregs (CD4 & Foxp3) and quantitative Foxp3 expression analysis. Results are expressed as mean ± standard deviation (SD). n = 3. #p < 0.05, ##p < 0.01 and, ####p < 0.001 between the selected groups. Dual-modulation of Tregs recruitment and function via Ab/HAPA@C-S MGs through CCL17 neutralization and PA release. (a) Scheme of Transwell migration assay for Tregs recruitment assessment. Experimental groups included: 1) Blank: complete medium; 2) Control: 50 ng/mL CCL17 and 50 ng/mL CCL22; 3) CCL22: containing 50 ng/mL CCL22 alone as a positive control for Tregs recruitment; 4) HAPA@C-S MGs: 50 ng/mL CCL17 and 50 mg/mL HAPA@C-S MGs; 5) Ab/HAPA@C-S MGs: 50 ng/mL CCL17 and 50 mg/mL Ab/HAPA@C-S MGs. After 4 h incubation, migrated cells in the lower chamber were stained with anti-CD4 and anti-CD25 antibodies and analyzed by flow cytometry to quantify Tregs migration efficiency. (b, c) Flow cytometry analysis and quantification of migrated Tregs after 4 h incubation. (d) Schematic mechanism of PA's effects on Tregs function. Cells were stimulated with different conditioned media as follows. 1) Blank: without any additional treatment; 2) HA: HA solution; 3) SP: sodium propionate (2 mM), serving as a positive control to assess the effect of SCFA on Tregs; 4) HAPA@C-S MGs: Tregs cultured in PA-release medium obtained from HAPA@C-S MGs after esterase incubation. (e, f) Flow cytometry of Tregs (CD4 & Foxp3) and quantitative Foxp3 expression analysis. Results are expressed as mean ± standard deviation (SD). n = 3. #p < 0.05, ##p < 0.01 and, ####p < 0.001 between the selected groups. Enhancement of Tregs function via HAPA-derived SCFA in vitro SCFAs such as PA are key metabolites derived from gut microbial fermentation of dietary fibers and have been increasingly recognized for their immunomodulatory roles [27]. PA has been shown to promote the differentiation, stability, and suppressive function of Tregs through mechanisms involving enhanced fatty acid oxidation (FAO) and improved mitochondrial fitness (Fig. 3d) [31,32,42]. This metabolic support is essential for maintaining the immunoregulatory capacity of Tregs, especially under inflammatory conditions [43]. Building on this understanding, we investigated whether the PA released from HAPA@C-S MGs could enhance Tregs functionality. To simulate the esterase-rich microenvironment of infarcted myocardium, HAPA@C-S MGs were incubated in esterase-containing medium (100 IU/mL) to collect PA-release medium for Tregs culture. The HA-treated group exhibited no significant upregulation of Foxp3, indicating that HA alone can't enhance Tregs functionality. In contrast, the sodium propionate (SP) group, in which PA was administered in its salt form, showed a marked increase in the proportion of Foxp3, confirming the immunomodulatory effect of PA on Tregs. Notably, Tregs co-incubated with the PA-release medium exhibited a comparable enhancement, with the percentage of Foxp3 rising significantly from 15% in the untreated group to approximately 27% (Fig. 3e and f). These findings collectively demonstrate that PA effectively promoted Tregs stability and function. As Foxp3 is a lineage-defining transcription factor for Tregs and a key indicator of their immunosuppressive capacity, these data further validate the therapeutic strategy of PA-mediated modulation of Tregs homeostasis. Modulation of macrophage polarization via HAPA-derived SCFA in vitro In addition to the systematic modulation of Tregs recruitment and functional enhancement, the role of PA in regulating macrophage polarization within a MI-mimicking microenvironment was further investigated. As a natural HDAC inhibitor, PA enhances histone acetylation, thereby upregulating anti-inflammatory gene expression such as IL-10 (Fig. 4a) [27,44].Fig. 4Immunomodulation of macrophage polarization by HAPA-derived propionic acid (PA) in vitro. (a) Schematic mechanism of PA as HDAC inhibitor promoting anti-inflammatory gene expression. Cells were stimulated with LPS (100 ng/mL) and IFN-γ (20 ng/mL) to induce M1 polarization and treated with different conditioned media as follows:1) Blank: PBS treatment without inflammatory stimulus; 2) Control: LPS/IFN-γ only; 3) HA: HA solution; 4) SP: sodium propionate (2 mM); 5) HAPA@C-S MGs/Esterase: PA-containing release medium from HAPA@C-S MGs. Cells were stained with FITC-anti-CD86 and APC-anti-CD206 antibodies, and analyzed via flow cytometry to evaluate M1/M2 polarization profiles. (b, c) Flow cytometry analysis of expression of CD86. (d, e) Flow cytometry analysis of expression of CD206. (f, g) ELISA quantification of TNF-α and IL-10. n ≥ 3. The dashed lines in panels (b, d) indicate the median fluorescence intensity (MFI) of the Blank group, serving as a visual reference for comparing the relative expression levels of CD86 (M1 marker) and CD206 (M2 marker) across treatment groups. ns, not significant, ∗∗p < 0.01, ∗∗∗p < 0.001, and ∗∗∗∗p < 0.0001 compared to the Control group. Immunomodulation of macrophage polarization by HAPA-derived propionic acid (PA) in vitro. (a) Schematic mechanism of PA as HDAC inhibitor promoting anti-inflammatory gene expression. Cells were stimulated with LPS (100 ng/mL) and IFN-γ (20 ng/mL) to induce M1 polarization and treated with different conditioned media as follows:1) Blank: PBS treatment without inflammatory stimulus; 2) Control: LPS/IFN-γ only; 3) HA: HA solution; 4) SP: sodium propionate (2 mM); 5) HAPA@C-S MGs/Esterase: PA-containing release medium from HAPA@C-S MGs. Cells were stained with FITC-anti-CD86 and APC-anti-CD206 antibodies, and analyzed via flow cytometry to evaluate M1/M2 polarization profiles. (b, c) Flow cytometry analysis of expression of CD86. (d, e) Flow cytometry analysis of expression of CD206. (f, g) ELISA quantification of TNF-α and IL-10. n ≥ 3. The dashed lines in panels (b, d) indicate the median fluorescence intensity (MFI) of the Blank group, serving as a visual reference for comparing the relative expression levels of CD86 (M1 marker) and CD206 (M2 marker) across treatment groups. ns, not significant, ∗∗p < 0.01, ∗∗∗p < 0.001, and ∗∗∗∗p < 0.0001 compared to the Control group. To induce M1 polarization, the RAW264.7 macrophages were co-treated with LPS (100 ng/mL) and IFN-γ (20 ng/mL), along with various experimental conditions for 24 h. First, the morphological changes of macrophages were observed (Fig. S10a). The unstimulated macrophages (M0 phenotype) exhibited a typical round morphology with smooth cell edges and limited pseudopodia formation, representing a resting cellular state. Upon co-stimulation with LPS and IFN-γ, the macrophages underwent classical pro-inflammatory M1 activation, characterized by enlarged cell size and increased pseudopodia (Fig. S10b). In contrast, the treatment with PA-release medium induced a pronounced phenotypic shift toward an anti-inflammatory M2-like morphology, with macrophages displaying elongated or spindle-shaped structures, smoother cell contours, and reduced protrusions (Fig. S10c). Subsequent flow cytometric analysis was performed after staining with CD86 for M1 phenotype or CD206 for M2 phenotype. Compared with the Control group, both the SP-treated group and the PA-release medium group exhibited a significant increase in the proportion of CD206+ cells, suggesting a phenotypic shift from pro-inflammatory M1 toward an anti-inflammatory M2 (Fig. 4b–e). In contrast, no notable phenotypic changes were observed in the HA group, indicating that HA alone can't regulate macrophage polarization. Further ELISA analysis of cytokine secretion demonstrated that treatment with PA-release medium significantly reduced pro-inflammatory tumor necrosis factor-alpha (TNF-α) production, while simultaneously upregulating anti-inflammatory IL-10 expression (Fig. 4f and g). These findings indicate that PA effectively promoted M2 polarization of macrophages, thereby contributing to anti-inflammatory immune regulation. Microenvironment-responsive regulation of CCL17, CES1, and PA in the infarcted myocardium The Ab/HAPA@C-S MGs were rationally designed to simultaneously address two critical immunoregulatory challenges in the infarcted myocardium: impaired Tregs homing caused by excessive CCL17 and compromised Tregs suppressive function resulting from an inflammatory environment. As depicted in Fig. 5a, the surface-conjugated anti-CCL17 antibodies were expected to neutralize local CCL17, thereby restoring Tregs homing to the infarct zone. Meanwhile, the elevated esterase activity in the post-MI microenvironment was anticipated to trigger enzymatic degradation of the HAPA, leading to PA release and enhancing Tregs immunosuppressive function (Fig. 5b).Fig. 5Immunoregulatory mechanism of Ab/HAPA@C-S MGs and expression of CCL17 and CES1 in infarcted myocardium. (a) Schematic illustration of the “recruitment and enhancement” immunoregulatory mechanism mediated by Ab/HAPA@C-S MGs in the infarcted myocardium. (b) Scheme of esterase-responsive degradation of the HAPA core and PA release from Ab/HAPA@C-S MGs. (c, d, g) Immunostaining images showing the expression of CCL17 in the infarcted myocardium at (c) day 3 and (d) day 5 post-MI, and (g) corresponding quantitative analysis. (e, f, h) Immunostaining images showing the expression of CES1 in the infarcted myocardium at (e) day 3 and (f) day 5 post-MI, and (h) corresponding quantitative analysis. (i) Relative expression intensity of PA in infarcted myocardial tissue. Brown color indicates CCL17/CES1 positive signals, and nuclei are counterstained with hematoxylin (blue). n ≥ 4. ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001, and ∗∗∗∗p < 0.0001 compared to the MI group. ns, not significant compared to the MI group or selected groups. Immunoregulatory mechanism of Ab/HAPA@C-S MGs and expression of CCL17 and CES1 in infarcted myocardium. (a) Schematic illustration of the “recruitment and enhancement” immunoregulatory mechanism mediated by Ab/HAPA@C-S MGs in the infarcted myocardium. (b) Scheme of esterase-responsive degradation of the HAPA core and PA release from Ab/HAPA@C-S MGs. (c, d, g) Immunostaining images showing the expression of CCL17 in the infarcted myocardium at (c) day 3 and (d) day 5 post-MI, and (g) corresponding quantitative analysis. (e, f, h) Immunostaining images showing the expression of CES1 in the infarcted myocardium at (e) day 3 and (f) day 5 post-MI, and (h) corresponding quantitative analysis. (i) Relative expression intensity of PA in infarcted myocardial tissue. Brown color indicates CCL17/CES1 positive signals, and nuclei are counterstained with hematoxylin (blue). n ≥ 4. ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001, and ∗∗∗∗p < 0.0001 compared to the MI group. ns, not significant compared to the MI group or selected groups. To investigate the early immunomodulatory effects of different microgel systems post MI, the expression levels of CCL17 and carboxylesterase 1 (CES1) within the infarcted region were evaluated on days 3 and 5 (Fig. 5c, d, g). The expression of CCL17 on day 3 was reduced in both the Ab@C-S MGs and Ab/HAPA@C-S MGs groups compared with the MI group, whereas no significant differences were observed in the C-S MGs and HAPA@C-S MGs groups. By day 5, the difference in CCL17 expression between the Ab@C-S MGs (CL17 antibody-modified microgels without HAPA encapsulation) and MI groups became less pronounced, suggesting that the neutralizing effect provided by antibody modification alone was transient. In contrast, the Ab/HAPA@C-S MGs group maintained a significantly lower CCL17 level than the MI group, indicating a more sustainable immunoregulatory effect. Regarding CES1 expression, a basal level was observed in the Sham group, whereas a marked elevation was observed in the MI group on day 3. At this time point, no significant differences were found among the treatment groups, suggesting that the early post-MI inflammatory response remained at an acute peak, and esterase activity primarily reflected a nonspecific stress-induced elevation. Notably, the elevated esterase level provided favorable conditions for the degradation of HAPA within the core of Ab/HAPA@C-S MGs, thereby initiating subsequent immunomodulatory processes (Fig. 5e, f, h). On day 5, CES1 expression in the Ab/HAPA@C-S MGs group decreased compared with the MI group, while no obvious changes were observed in the other groups. The endogenous level of PA in the infarcted myocardium on day 5 was quantitatively analyzed by liquid chromatography-mass spectrometry‌ (LC-MS) (Fig. 5i). The Sham group exhibited a relatively high basal PA level, reflecting the physiological presence of short-chain fatty acids under normal cardiac metabolic conditions. In contrast, MI resulted in a marked reduction in the local PA content. Notably, both the C-S MGs and Ab@C-S MGs groups displayed PA levels comparable to the MI group. In contrast, treatment with the HAPA@C-S MGs and Ab/HAPA@C-S MGs elevated myocardial PA levels to values comparable to, or even exceeding, that of the Sham group. This restoration supports that HAPA serves as an effective enzymatically degradable PA reservoir and the upregulated esterase activity (CES1) in the post-MI microenvironment can efficiently trigger its degradation and PA release in situ. Collectively, the Ab/HAPA@C-S MGs exhibited early-stage immunomodulatory properties following MI. This regulatory process can be characterized as a dual-stage “recruit and enhance” paradigm: initially, the anti-CCL17 antibody eliminates excessive inflammatory chemotactic signals to facilitate Tregs recruitment and establish immunosuppressive cues (“recruit”), followed by esterase-triggered degradation of HAPA and release of PA to enhance Tregs immunosuppressive function (“enhance”). This coordinated immunomodulatory cascade promotes resolution of inflammation and reconstruction of immune homeostasis, thereby creating a favorable microenvironment for myocardial repair and functional recovery. Immunomodulation in mouse MI model in vivo To assess changes in T cell subsets within the infarcted myocardium, immunofluorescence staining for IL-17 and Foxp3 was performed to identify pro-inflammatory Th17 cells and immunosuppressive Tregs 5 d post-MI, respectively. IL-17 is a prototypical inflammatory cytokine secreted by Th17 cells that contributes to the maintenance of local chronic inflammation, while Foxp3 is a transcription factor specifically expressed by Tregs and serves as a direct indicator of their immunoregulatory function [45,46]. Compared to the MI group, the Ab/HAPA@C-S MGs treatment group exhibited a significant increase-approximately 2.8-fold in the number of Foxp3+ Tregs (Fig. 6a–e), accompanied by a marked reduction in IL-17+ Th17 cells (Fig. 6b–f). Further comparison among the treatment groups revealed that the C-S MGs group, which contains only HA in the core, failed to significantly improve Tregs recruitment or suppress Th17 infiltration, indicating that HA alone lacks substantial immunomodulatory capacity. The HAPA@C-S MGs group, capable of releasing PA in response to esterase, enhanced Tregs functionality and demonstrated modest immune improvement. Similarly, the Ab@C-S MGs group, designed to neutralize CCL17 and restore the chemotactic gradient, facilitated Tregs recruitment and showed partial efficacy. However, neither of these groups achieved the same level of Tregs modulation as the Ab/HAPA@C-S MGs group. By simultaneously releasing PA to enhance Tregs function and neutralizing CCL17 to boost their recruitment, the Ab/HAPA@C-S MGs established a “recruit and enhance” dual regulatory strategy.Fig. 6Immunomodulatory effects of Ab/HAPA@C-S MGs in therapy of mouse MI for 5 d in vivo. (a, b) Immunofluorescence staining images of Foxp3 (green) and IL-17 (red), and (c, d) immunohistochemical staining images of CD86 (M1) and CD206 (M2) macrophages in infarct regions, where cell nuclei were counter-staining with DAPI (blue). (e, f) Quantitative analysis of Foxp3+ Tregs and IL-17+ Th17 cells in infarcted region. (g, h) Quantitative analysis of CD86+ (M1) and CD206+ (M2) macrophages in infarcted region. Results are expressed as mean ± standard deviation (SD). n = 3. #p < 0.05, ##p < 0.01 and ###p < 0.001 between the selected groups; ∗p < 0.05, ∗∗p < 0.01, and ∗∗∗∗p < 0.0001 and ns, not significant compared to the MI group or selected groups. Immunomodulatory effects of Ab/HAPA@C-S MGs in therapy of mouse MI for 5 d in vivo. (a, b) Immunofluorescence staining images of Foxp3 (green) and IL-17 (red), and (c, d) immunohistochemical staining images of CD86 (M1) and CD206 (M2) macrophages in infarct regions, where cell nuclei were counter-staining with DAPI (blue). (e, f) Quantitative analysis of Foxp3+ Tregs and IL-17+ Th17 cells in infarcted region. (g, h) Quantitative analysis of CD86+ (M1) and CD206+ (M2) macrophages in infarcted region. Results are expressed as mean ± standard deviation (SD). n = 3. #p < 0.05, ##p < 0.01 and ###p < 0.001 between the selected groups; ∗p < 0.05, ∗∗p < 0.01, and ∗∗∗∗p < 0.0001 and ns, not significant compared to the MI group or selected groups. In addition, the Ab/HAPA@C-S MGs exhibited significant immunomodulatory potential at the level of innate immunity. Following MI, an excessive pro-inflammatory response can exacerbate tissue damage and impair the healing process. This is particularly critical during the acute phase, when the infiltration and phenotypic polarization of macrophages play a vital role in determining the outcome of tissue remodeling. To further evaluate the immunoregulatory effects of Ab/HAPA@C-S MGs during the acute phase post MI, immunohistochemical staining was performed to assess the expression of CD86 (M1) and CD206 (M2) in the infarcted myocardium (Fig. 6c–g). Substantial accumulation of CD86+ macrophages was observed in the infarcted region of the untreated MI group 5 d post MI, indicating a predominantly M1-type inflammatory profile. In contrast, the mice treated with the Ab/HAPA@C-S MGs displayed a marked reduction in the CD86+ cells alongside a significant increase in the CD206+ macrophages (Fig. 6d–h), suggesting a successful shift in macrophage polarization from a pro-inflammatory to a reparative phenotype. The enrichment of M2 macrophages is beneficial for apoptotic cell clearance, extracellular matrix remodeling, and neovascularization-key processes that support early cardiac remodeling and functional recovery [47]. Besides the influence on local cardiac immune microenvironment, the post MI inflammation also triggers systemic immune dysregulation, which can further impair cardiac recovery [2]. To evaluate the impact of Ab/HAPA@C-S MGs on systemic inflammation, serum cytokine levels were measured using ELISA. Key pro-inflammatory cytokines, including TNF-α and IL-6, along with the anti-inflammatory cytokine IL-10, were quantified to assess the overall inflammatory status. Compared with the untreated MI group, the mice treated with the Ab/HAPA@C-S MGs exhibited significantly reduced levels of TNF-α and interleukin-6 (IL-6), while IL-10 was markedly elevated (Fig. S11). These findings indicate that the microgel system realized immunomodulatory effects at the infarct site, which in turn attenuated systemic inflammatory responses, thereby contributing to a more favorable systemic environment for myocardial healing. Cardiomyocyte apoptosis is a major pathological feature of early MI, and contributes to adverse cardiac remodeling. To investigate the cytoprotective potential of Ab/HAPA@C-S MGs, cardiomyocyte apoptosis in infarcted tissue was assessed via Terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) staining, which detects DNA fragmentation associated with programmed cell death [48]. TUNEL+ cells were observed in the untreated MI group, which is indicative of extensive apoptosis induced by ischemic injury. In contrast, the Ab/HAPA@C-S MGs-treated group showed a substantial reduction in the TUNEL+ cells, suggesting that the microgel system effectively preserved cardiomyocyte viability (Fig. S12). This protective effect is attributed to the attenuation of inflammation and enhanced immunoregulation provided by the microgel system of dual-functions during the acute post MI phase. Evaluation of therapeutic effects in vivo To systematically evaluate the long-term therapeutic potential of Ab/HAPA@C-S MGs in promoting post-MI cardiac repair, a 28-day study was conducted using a rat MI model, focusing on neovascularization and myocardial electrical coupling. CD31, a marker of vascular endothelial cells, and Cx43, a key gap junction protein responsible for synchronized electrical conduction in cardiomyocytes, were selected as the primary indicators [49]. At day 28 post-MI, heart tissue analysis revealed that the Ab/HAPA@C-S MGs group exhibited markedly increased vascular density in the peri-infarct region, with significantly stronger CD31 and α-SMA signals compared to both the MI group and other microgel-treated groups (Fig. S13a and b). Although the treatment with either HAPA@C-S MGs or Ab@C-S MGs alone also moderately enhanced angiogenesis-presumably through Tregs activation or chemokine gradient restoration, the dual-functional Ab/HAPA@C-S MGs group demonstrated the most pronounced pro-angiogenic effect. This result suggests that the combination of Tregs recruitment and activation realized a synergistic immunoregulatory effect that more effectively supports neovascularization. In terms of electrophysiological remodeling, expression of Cx43, which is typically downregulated after MI, was most strongly restored in the Ab/HAPA@C-S MGs group, outperforming both the single-functional treatment groups (Fig. S13a and b). This recovery indicates superior reconstruction of gap junctions and enhanced myocardial electrical signal propagation. Furthermore, immunostaining for cTnT, a marker of cardiomyocyte viability and contractile function, showed a significantly higher density of cTnT+ cells in the Ab/HAPA@C-S MGs group compared to other groups (Fig. S13a and c), further confirming the protective and functional benefits of the strategy for Tregs. For structural remodeling assessment, wheat germ agglutinin (WGA) staining was employed to specifically label cardiomyocyte membranes, enabling the visualization of cross-sectional area (CSA) as an indicator of cardiac hypertrophy. The staining results show a substantial increase in CSA in the MI group, reflecting pronounced pathological hypertrophy following ischemic injury. The Ab/HAPA@C-S MGs group exhibited the most significant reduction in CSA, indicating a superior capacity to attenuate adverse structural remodeling (Fig. S14). Collectively, these findings demonstrate that the Ab/HAPA@C-S MGs significantly enhanced both the vascular regeneration and electrical signal conduction, while also most effectively reduced cardiomyocyte hypertrophy as evidenced by WGA staining, highlighting their comprehensive therapeutic potential in long-term myocardial repair post MI. Evaluation of cardiac functions and fibrosis in vivo To further assess the therapeutic efficacy of Ab/HAPA@C-S MGs in promoting myocardial repair, comprehensive evaluations of cardiac functions and fibrosis progression were performed 28 d post MI using echocardiography, hematoxylin-eosin (H&E) staining, and Masson's trichrome staining. Echocardiographic measurements, including LVEF (left ventricular ejection fraction), LVFS (left ventricular fractional shortening), LVEDV (left ventricular end-diastolic volume), LVESV (left ventricular end-systolic volume) demonstrated significant functional improvements in the Ab/HAPA@C-S MGs group compared with the untreated MI group (Fig. 7a−c). Specifically, the LVEF reached 62% and LVFS was 29% in the Ab/HAPA@C-S MGs group, notably higher than those observed in the HAPA@C-S MGs group (LVEF: 51%, LVFS: 23%) and the Ab@C-S MGs group (LVEF: 49%, LVFS: 22%). Meanwhile, both the LVEDV and LVESV, which represent the indicators of ventricular dilatation, were markedly reduced in the Ab/HAPA@C-S MGs group, indicating improved ventricular remodeling and preserved cardiac contractility. In contrast, elevated LVEDV and LVESV values were observed in the MI group and single-functional material groups, reflecting more severe post MI ventricular dilation and dysfunction (Fig. S16).Fig. 7Functional and structural improvements after being treated with Ab/HAPA@C-S MGs in rat post MI for 28 d. (a) Representative M-mode echocardiography images. (b, c) Echocardiography measurement of left ventricular ejection fraction (LVEF) and fractional shortening (LVFS). (d) Masson's trichrome staining evaluating cardiac fibrosis, where fibrotic tissue appears blue and myocardium appears red. Upper panel: whole-heart cross section; lower panel: magnified view of the infarct areas shown in the red boxes in the upper panel. (e) Quantitative analysis of fibrotic area to the whole-heart cross-section. Results are expressed as mean ± standard deviation (SD). n ≥ 3. #p < 0.05 and ##p < 0.01 between the selected groups; ∗p < 0.05, ∗∗p < 0.01, ∗∗∗∗p < 0.0001 and ns, not significant compared to the MI group. Functional and structural improvements after being treated with Ab/HAPA@C-S MGs in rat post MI for 28 d. (a) Representative M-mode echocardiography images. (b, c) Echocardiography measurement of left ventricular ejection fraction (LVEF) and fractional shortening (LVFS). (d) Masson's trichrome staining evaluating cardiac fibrosis, where fibrotic tissue appears blue and myocardium appears red. Upper panel: whole-heart cross section; lower panel: magnified view of the infarct areas shown in the red boxes in the upper panel. (e) Quantitative analysis of fibrotic area to the whole-heart cross-section. Results are expressed as mean ± standard deviation (SD). n ≥ 3. #p < 0.05 and ##p < 0.01 between the selected groups; ∗p < 0.05, ∗∗p < 0.01, ∗∗∗∗p < 0.0001 and ns, not significant compared to the MI group. Histological analyses further corroborated these findings. H&E staining demonstrated improved myocardial preservation in the Ab/HAPA@C-S MGs group, with less inflammatory infiltration and better-organized cardiomyocyte alignment compared to other groups (Fig. S17). Although moderate histological improvement was found in the HAPA@C-S MGs and Ab@C-S MGs groups likely due to either reduced inflammation or partial chemokine modulation, only the Ab/HAPA@C-S MGs group restored myocardial architecture to a near-normal state. Similarly, Masson's trichrome staining highlighted a significant reduction in fibrotic area in the Ab/HAPA@C-S MGs group, revealing decreased extracellular matrix deposition and inhibition of maladaptive remodeling (Fig. 7d and e). This anti-fibrotic effect aligns with the enhanced immunomodulatory capacity of the dual-treatment system. These results show Ab/HAPA@C-S MGs as a dual-stage, microenvironment-adaptive immunoregulatory platform that realized both Tregs recruitment and functional reinforcement to achieve sustained myocardial repair after infarction. In contrast to existing strategies that rely on adoptive Tregs transfer or systemic immunosuppression, this system enables homing and stabilization of endogenous Tregs through localized chemokine guidance and metabolite-mediated immune programming in situ. By coupling CES1-responsive degradation with PA release, the platform dynamically matches immune activation with the evolving infarct microenvironment, thereby providing a non-cell-based alternative to cellular immunotherapy. Evaluation of immunometabolic mechanisms in MI repair via transcriptomic analysis To systematically elucidate the mechanisms underlying the therapeutic effects of Ab/HAPA@C-S MGs on MI, a comprehensive transcriptomic analysis was performed, including differential gene expression profiling, Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway annotations and enrichment, and targeted analysis of key genes. As shown in Fig. 8a–c, compared with the Sham group, the MI group exhibited extensive transcriptional alterations, confirming successful model establishment. Notably, the Ab/HAPA@C-S MGs-treated group showed a reduced number of differentially expressed genes relative to the MI group, suggesting a partial restoration of MI-induced transcriptional dysregulation.Fig. 8Transcriptomic profiling revealing coordinated immunometabolic regulation underlying Ab/HAPA@C-S MGs-mediated cardiac repair after MI. (a-c) Statistical analysis of differentially expressed genes (DEGs) among experimental groups, including comparisons between Sham vs MI and MI vs Ab/HAPA@C-S MGs group, showing the overall transcriptional alterations induced by MI and their modulation after treatments. (d,e) KEGG pathway enrichment analysis and annotations of DEGs for MI vs Sham. (f,g) KEGG pathway enrichment analysis and annotations of DEGs for Ab/HAPA@C-S MGs vs MI, highlighting pathways associated with inflammation, immune response, and metabolic regulation. Transcriptomic profiling revealing coordinated immunometabolic regulation underlying Ab/HAPA@C-S MGs-mediated cardiac repair after MI. (a-c) Statistical analysis of differentially expressed genes (DEGs) among experimental groups, including comparisons between Sham vs MI and MI vs Ab/HAPA@C-S MGs group, showing the overall transcriptional alterations induced by MI and their modulation after treatments. (d,e) KEGG pathway enrichment analysis and annotations of DEGs for MI vs Sham. (f,g) KEGG pathway enrichment analysis and annotations of DEGs for Ab/HAPA@C-S MGs vs MI, highlighting pathways associated with inflammation, immune response, and metabolic regulation. KEGG enrichment analysis (Fig. 8d–e) revealed that MI-associated genes were mainly enriched in pathways related to inflammation, immune response, and metabolic disturbance such as cytokine-cytokine receptor interaction, complement and coagulation cascades, peroxisome proliferator-activated receptor (PPAR) signaling pathway, and fatty acid degradation. In contrast, Ab/HAPA@C-S MGs treatment was associated with enrichment in pathways including IL-17 signaling, TNF signaling, and ECM-receptor interaction, indicating modulation of inflammatory signaling and extracellular matrix remodeling (Fig. 8f–g). Further analysis of up- and downregulated genes demonstrated that treatment was associated with upregulation of pathways related to immune regulation and lipid metabolism, alongside downregulation of pro-inflammatory and stress-related pathways (Fig. 9a−b, Fig. S18). Consistently, key gene expression analysis (Fig. 9c) showed that MI induced upregulation of pro-inflammatory and epigenetic regulators (e.g., Ccl17, Il1b, Tnf, and Hdac1/2/3) and downregulation of immune-regulatory and metabolic genes (e.g., Ccr4, Foxp3, and Il10), whereas these alterations were partially reversed in the Ab/HAPA@C-S MGs group. Targeted KEGG enrichment analysis of key genes (Fig. 9d) further indicated that these genes were associated with pathways such as cytokine-cytokine receptor interaction, Th17 cell differentiation, TGF-β signaling, efferocytosis, and PPAR signaling, which are closely related to immune regulation, inflammation resolution, and metabolic reprogramming.Fig. 9Analysis of differentially expressed genes and key gene-related pathways after Ab/HAPA@C-S MGs treatment. (a,b) KEGG annotations analysis of upregulated (a) and downregulated (b) DEGs in the Ab/HAPA@C-S MGs vs MI comparison, revealing pathway-level shifts associated with treatment-induced transcriptional reprogramming. (c) Heatmap showing the expression patterns of representative key genes across all groups, including genes related to inflammation, immune regulation, metabolism, and epigenetic regulation. (d) Targeted KEGG pathway enrichment analysis of selected key genes, indicating their association with pathways involved in immune regulation, inflammation resolution, and metabolic reprogramming such as cytokine-cytokine receptor interaction, Th17 cell differentiation, TGF-β signaling, efferocytosis, and PPAR signaling pathway. Analysis of differentially expressed genes and key gene-related pathways after Ab/HAPA@C-S MGs treatment. (a,b) KEGG annotations analysis of upregulated (a) and downregulated (b) DEGs in the Ab/HAPA@C-S MGs vs MI comparison, revealing pathway-level shifts associated with treatment-induced transcriptional reprogramming. (c) Heatmap showing the expression patterns of representative key genes across all groups, including genes related to inflammation, immune regulation, metabolism, and epigenetic regulation. (d) Targeted KEGG pathway enrichment analysis of selected key genes, indicating their association with pathways involved in immune regulation, inflammation resolution, and metabolic reprogramming such as cytokine-cytokine receptor interaction, Th17 cell differentiation, TGF-β signaling, efferocytosis, and PPAR signaling pathway. Collectively, these findings suggest that Ab/HAPA@C-S MGs treatment is associated with coordinated regulation of inflammation, immune responses, and metabolism, which contribute to improved cardiac repair after MI. Conclusion In this study, a core-shell microgel system (Ab/HAPA@C-S MGs) was designed for immunomodulation post MI, aiming to recruit Tregs and enhance their immunosuppressive function. This dual-regulation strategy was implemented by integrating CCL17-neutralizing antibodies and PA within a esterase-degradable polymer framework. Studies in vitro demonstrated that Ab/HAPA@C-S MGs effectively neutralized excess CCL17 and achieved sustained PA release under esterase-mimicking conditions, confirming their controlled release behavior and immune-intervention potential. Functional assays further revealed that the system significantly promoted Tregs migration, upregulated Foxp3 expression, enhanced IL-10 secretion, and induced macrophage polarization toward an anti-inflammatory M2 phenotype, collectively shaping a pro-regenerative immune microenvironment. Evaluations in MI models showed that the Ab/HAPA@C-S MGs facilitated Tregs enrichment while suppressing Th17 accumulation in infarcted myocardium, attenuated pro-inflammatory cytokine expression, reduced fibrosis, and improved cardiac functions. In summary, by integrating Tregs recruitment with functional activation, the Ab/HAPA@C-S MGs system demonstrated a good therapeutic efficacy compared to the single-modality strategies in attenuating immune stress, preserving cardiac functions, and promoting long-term myocardial repair post MI. This dual-regulatory platform offers a comprehensive immunoregulatory approach, showing good promise as an effective intervention for post-MI cardiac tissue repair. Materials and methods Materials Sodium hyaluronate (HA, Mw = 600 kDa) was purchased from RHAWN (China). HA (Mw = 12 kDa) was purchased from Jiangsu Haifei Biotechnology Co., Ltd. (China). Hyaluronic acid methacryloyl (HAMA, MW = 150 kDa) was purchased from EFL-tech (China), with a MA grafting ratio of 30-40%. Lithium phenyl-2,4,6-trimethylbenzoylphosphinate (LAP), dopamine hydrochloride, tris(hydroxymethyl)aminomethane hydrochloride (Tris-HCl), ethyldimethylaminopropyl carbodiimide (EDC), sodium hydroxide (NaOH), dimethyl sulfoxide (DMSO), Span 80, hexane, ethanol, and phosphate-buffered saline (PBS) were obtained from Aladdin (China). Fluorescein isothiocyanate-conjugated poly-L-lysine (PLL-FITC, Mw = 5000) was bought from MeloPEG (China). Mineral oil, sodium pyruvate and propionic anhydride were sourced from Sigma-Aldrich (USA). Hydrochloric acid (HCl) and N,N-dimethylformamide (DMF) were provided by Sinopharm Chemical Reagent Co., Ltd (China). N-Hydroxysuccinimide-biotin (NHS-biotin) and streptavidin were acquired from Solarbio Life Sciences (China). The biotinylated C-C motif chemokine ligand 17 (CCL17) antibody was purchased from Cloud-Clone Corp. (China). Roswell Park Memorial Institute (RPMI 1640), Dulbecco's modified Eagle medium (DMEM) and fetal bovine serum (FBS) were supplied by Gibco (USA). β-Mercaptoethanol was purchased from Macklin (China). Recombinant CCL17, HEPES (pH7.3), cell counting kit-8 (CCK-8), and the TdT-mediated dUTP Nick End Labeling (TUNEL) apoptosis detection kit were obtained from Beyotime Biotechnology (China). Recombinant CCL22 was purchased from Gibco (Thermo Fisher Scientific, USA). Fluorescently labeled antibodies (FITC-CD4, APC-CD206, FITC-CD86, BV421-CD25 and PE-Foxp3) and cyanine3-streptavidin (Cy3-SA) were procured from BioLegend (USA). ELISA kits for CCL17, tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6), and interleukin-10 (IL-10) were purchased from Boster Biological Technology (China). Ultrapure water (18.2 MΩ cm) was obtained using a Millipore Milli-Q system. Synthesis and characterization of HAPA To synthesize HAPA, the sodium hyaluronate (HA, 1 g, 0.008 mmol, Mw = 12 kDa) was dissolved in a mixed solvent of DMF (30 mL) and ultrapure water (70 mL) under continuous stirring. After the solution was cooled in an ice bath, 5 mL of propionic anhydride (39 mmol) was added dropwise to initiate the acylation reaction. During the reaction, 5 M NaOH solution was alternately added to maintain the pH between 8 and 9. The reaction proceeded under ice-bath condition with constant stirring for 24 h. Upon completion, the reaction mixture was slowly added into at least five volumes of ice-cold absolute ethanol to precipitate the product. The resulting precipitate was collected by centrifugation at 10,000 r/min for 10 min, redissolved in ultrapure water, and transferred into a dialysis bag (MWCO 3500 Da). Dialysis was performed against ultrapure water for 5 d to remove unreacted propionic anhydride and small molecular impurities. The obtained HAPA was lyophilized and stored at −20 °C for further use. 1H nuclear magnetic resonance (1H NMR) spectroscopy (DMX400, Bruker Germany) and Fourier transform infrared (FTIR, Nicolet iS20, Thermo Fisher Scientific, USA) spectroscopy were used to characterize the structure of HAPA. Preparation and characterization of HAPA@C-S MGs The HAPA@C-S MGs were prepared using a microfluidic chip technology combined with photoinitiated crosslinking according to the method described in our previous work [50]. First, the shell solution was made up of hyaluronic acid-methylacrylate (HAMA), PEGDA and a photoinitiator (LAP) with concentrations of 2% (w/w), 5% (w/w) and 0.5% (w/w), respectively. In a separate preparation, the core solution was made by mixing the synthesized HAPA (10%, w/w) with 1% (w/w) HA (600 kDa). The continuous phase comprised of mineral oil mixed with span 80 (5.0%, w/v). PLL-FITC was incorporated into the core solution to enable visualization of the core-shell structure. These solutions were fed into separate channels within the microfluidic chip, and the flow rate of shell phase, core phase and continuous phase were set at 150 μL/h, 150 μL/h and 1000 μL/h, respectively. The microfluidic system employed photoinitiated crosslinking under UV light (INTELLIRAY400, Uvitron USA) for 30 min (360 mW/cm2) to prepare stable microgels with a core-shell structure. After the crosslinking reaction, the HAPA@C-S MGs were collected, washed with hexane and ethanol for 3 times to eliminate un-crosslinked materials. Finally, the resulted HAPA@C-S MGs were stored in PBS and further use. The HAPA@C-S MGs in an aqueous environment were observed with an optical microscope (Axio Observer 3, Zeiss, Germany). The microgels were characterized by scanning electron microscopy (SEM, EM-30+, COXEM, Korea) to examine the surface morphology and particle size after lyophilization. Surface modification of HAPA@C-S MGs The surface modification of HAPA@C-S MGs was accomplished through sequential chemical reactions. First, the HAPA@C-S MGs were dispersed in PBS and coated with a 1% dopamine solution (prepared in 10 mM Tris-HCl buffer, pH 8.5). After 12 h of incubation at room temperature, the PDA was uniformly deposited onto the microgel surface, yielding PDA-coated microgels (denoted as P@MGs). The excess dopamine was removed by PBS washing. The morphology of P@MGs was characterized by SEM. Meanwhile, energy-dispersive X-ray spectroscopy (EDS) mapping was performed to further confirm the presence of nitrogen (N) element on the microgels. X-Ray photoelectron spectroscopy (XPS) was performed on a K-Alpha spectrometer (Thermo Fisher Scientific, USA) for chemical structure characterization of P@MGs. The freeze-dried samples were pelletized, mounted on a conductive double-sided carbon tape, and loaded into the chamber (pressure <2.0 × 10−7 mbar pre-test). Monochromatic Al Kα radiation was used as excitation source (12 kV, 6 mA, 400 μm spot). Survey scans (150 eV pass energy, 1.0 eV step) and high-resolution scans (50 eV pass energy, 0.1 eV step) were performed for C 1s, N 1s, and O 1s. Charge compensation was applied when needed. Binding energies were calibrated to C 1s (284.8 eV). Spectral deconvolution was carried out with Avantage software (Shirley background subtraction, Gaussian-Lorentzian fitting). The P@MGs were incubated with 5 mg/mL NHS-biotin and 1 mM EDC for 6 h to ensure robust biotin conjugation, yielding PB@MGs. Streptavidin (SA) immobilization (PBSA@MGs) was verified by incubating biotinylated microgels with Cy3-labeled SA (Cy3-SA, 5 μg/mL). Prior to washing, the fluorescence intensity of the supernatant was quantitatively measured using a microplate reader (Fluoroskan FL, Thermo Fisher Scientific, USA) to evaluate SA binding efficiency. The unbound SA was removed by PBS washing. The microgels were then analyzed under fluorescence microscopy. Finally, the Ab/HAPA@C-S MGs were obtained by incubating the PBSA@MGs with 5 μg/mL biotinylated CCL17 antibody (termed Ab), which specifically conjugated to the SA-coated surface via biotin-streptavidin interaction. Rheological analysis of Ab/HAPA@C-S microgels The viscoelastic properties of wet Ab/HAPA@C-S microgels were evaluated using a rheometer equipped with an 8 mm parallel plate fixture (Discovery HR20, Waters, USA). Measurements were performed at 25 °C within the linear viscoelastic region, using a constant strain of 1%. Frequency sweep tests were conducted from 20 Hz to 0.1 Hz, recording the storage modulus (G′) and loss modulus (G″) over the tested range. Swelling properties of Ab/HAPA@C-S microgels Swelling behavior of the microgels was characterized as follows. Lyophilized microgels were incubated in PBS at 37 °C for 24 h to reach equilibrium swelling. The wet weight (Ww) was recorded after removing excess surface PBS. The samples were then lyophilized again to determine the dry weight (Wd). The swelling ratio (SR) was calculated as: SR = (Ww - Wd)/Wd × 100%. CCL17 neutralization via Ab/HAPA@C-S MGs To systematically evaluate the CCL17-neutralizing capability of microgels and to distinguish the contribution of each surface modification step, four experimental groups were set up: Blank (PBS), HAPA@C-S MGs, Ab, and Ab/HAPA@C-S MGs. To simulate CCL17 overexpression in the post-MI microenvironment, 10 ng/mL of CCL17 was added to the culture medium of each group. The experimental group was incubated with surface-modified microgels at 37 °C for 2 h to facilitate CCL17 binding. Post-incubation, the CCL17 concentrations in the culture mediums were quantified via ELISA, and the differences between groups were analyzed to evaluate the neutralization capacity of the antibody-conjugated microgels. Analysis of PA released from HAPA@C-S MGs To evaluate the release behavior of PA without and with the existence of esterase, the HAPA or HAPA@C-S MGs were dissolved or dispersed in PBS, into which esterase (100 IU/mL) was added [20]. The reaction was carried out at 37 °C with gentle stirring (100 rpm), before the mediums were collected at various time points (0−24 h). At each time point, an equal volume of fresh PBS was supplemented to ensure consistent experimental conditions. The supernatant was then analyzed for PA concentration using Ultra Performance Liquid Chromatography (UPLC, Agilent1100, USA). Isolation and culture of primary Tregs The primary Tregs were isolated from the mouse spleen using the EasySep Mouse CD4+CD25+ Regulatory T Cell Isolation Kit II (STEMCELL Technologies, Canada), following the manufacturer's protocol. All procedures were approved by the Laboratory Animal Welfare and Ethics Review Committee of Zhejiang University (approval number: ZJU20241137). Briefly, the mice were euthanized by cervical dislocation in accordance with institutional ethical guidelines. The harvested spleens were rinsed with RoboSep™ Buffer (STEMCELL Technologies, Canada) to remove surface contaminants. They were then minced and passed through a mesh to obtain a single-cell suspension, which was filtered through a 70 μm cell strainer to remove undigested tissue fragments. The resulted homogeneous cell suspension was separated using magnetic beads to isolate Tregs from other populations. For routine culture, 1 × 106 cells were seeded in a 12-well plate, and maintained in complete T cell culture medium (RPMI 1640 supplemented with 10% heat-inactivated FBS, 100 U/mL penicillin, 100 μg/mL streptomycin, 1 mM sodium pyruvate, 10 mM HEPES, and 50 μM β-mercaptoethanol) with IL-2 (40 ng/mL; ab259380, abcam, UK). All subsequent experiments involving Tregs were performed using cells at day 4 post-isolation following expansion in vitro due to the prosperous proliferation of Tregs at this stage. Tregs recruitment in vitro To evaluate the chemotactic effect of CCL17 antibody-modified microgels on Tregs recruitment, a Transwell migration assay was performed using 24-well plates with 5 μm pore-size inserts (Costar, Corning, USA). One million primary Tregs were seeded into the upper chambers in 200 μL serum-free medium, while 600 μL of conditioned medium was added to the lower chambers to simulate different chemotactic microenvironments. The experimental groups included: 1) Blank: containing only complete medium without cytokines or microgels; 2) Control: supplemented with 50 ng/mL CCL17 and 50 ng/mL CCL22 to mimic the pro-inflammatory milieu post-MI; 3) CCL22: containing 50 ng/mL CCL22, serving as a positive control for promoting Tregs recruitment; 4) HAPA@C-S MGs: with 50 ng/mL CCL17 and 50 mg/mL HAPA@C-S MGs to test the recruitment without CCL17 neutralization; and 5) Ab/HAPA@C-S MGs: with 50 ng/mL CCL17 and 50 mg/mL Ab/HAPA@C-S MGs to assess the specific effect of CCL17 blockade on Tregs migration. After 4 h of incubation at 37 °C, the cells that migrated to the lower chambers were collected, stained with anti-CD4 and anti-CD25 antibodies, and analyzed via a flow cytometer (NovoCyte, ACEA, USA) to quantify the percentage of recruited Tregs (CD4+CD25+). Tregs immunoregulatory function assay in vitro To evaluate the effect of HAPA@C-S MGs on enhancing Tregs immune function, a PA-containing release medium was prepared by incubating the HAPA@C-S MGs (100 mg/mL) in RPMI 1640 medium supplemented with esterase (100 IU/mL) for 24 h at 37 °C to simulate the enzyme-rich post-MI microenvironment. After incubation, the release medium was collected, and the esterase was removed by ultrafiltration. The release medium was supplemented with 10% heat-inactivated FBS and 40 ng/mL IL-2 to support Tregs survival and function. The Tregs were seeded into 24-well plates at a density of 1 × 106 cells per well. The experimental setup included the following groups: 1) Blank: without any additional treatment; 2) HA: serving as an evaluation of whether HA alone affects Tregs function; 3) SP (sodium propionate, 2 mM): serving as a positive control to assess the effect of SCFA on Tregs; 4) HAPA@C-S MGs: Tregs cultured in PA-release medium obtained from HAPA@C-S MGs after esterase incubation to evaluate the functional enhancement conferred by enzyme-triggered PA release from the hydrogel system. After 24 h of culture under these conditions, the immunosuppressive function of Tregs was evaluated via flow cytometry using anti-CD4 and anti-Foxp3 antibodies to determine the proportion of Foxp3. Modulation of macrophage polarization in vitro To assess the effect of HAPA@C-S MGs on RAW264.7 cell polarization, a PA-release medium was prepared according to the procedure described in Section 4.9. RAW264.7 cells were seeded into 12-well plates at a density of 1 × 106 cells per well in complete DMEM, and allowed to adhere for 3 h. Subsequently, LPS (100 ng/mL) and IFN-γ (20 ng/mL) were added to the FBS-free medium to induce inflammatory polarization. The RAW264.7 cells were treated with different conditioned media according to the following experimental groups: 1) Blank: PBS treatment without inflammatory stimulus; 2) Control: LPS/IFN-γ treatment only; 3) HA: LPS/IFN-γ + HA solution; 4) SP: LPS/IFN-γ + sodium propionate (2 mM); 5) HAPA@C-S MGs: LPS/IFN-γ + PA-release medium obtained from HAPA@C-S MGs. After 24 h of incubation, the cells were harvested and stained with FITC-anti-CD86 or APC-anti-CD206 antibodies to detect M1 and M2 macrophage surface markers, respectively. Flow cytometry was performed to analyze the proportions of CD86+ and CD206+ cells, representing M1 and M2 phenotypes, respectively. Additionally, the culture supernatants were collected for ELISA analysis to quantify the levels of pro-inflammatory cytokine TNF-α and anti-inflammatory cytokine IL-10, further validating the modulatory effect of PA on macrophage polarization. Animal experiment To align with the established experiments in vitro, and given that most Tregs validation studies utilize murine models, the experiments in vivo were performed on C57BL/6 mice (20 ± 5 g, n = 42; obtained from Hangzhou Medical College). Ethical clearance for the animal research was provided by Zhejiang Center of Laboratory Animals under the guideline of Institutional Animal Care and Use Committee (approval code: ZJCLA-IACUC-20011085). The mice were anesthetized with an intraperitoneal injection of 170 μL of 1% pentobarbital prior to experimentation. Following anesthesia, the mouse was positioned supine, and a neck incision was made to expose the trachea for intubation and ventilation. The heart was accessed via left thoracotomy. After pericardial removal, the left anterior descending coronary artery (LAD) was ligated with a silk suture to induce left ventricular infarction. Successful MI was confirmed by visible myocardial pallor. Subsequently, 5 μL of microgels was injected at two sites within the infarcted region using a microinjection needle. The microgels were initially prepared at 50 mg/mL and subsequently concentrated by centrifugation to remove nearly all free water prior to injection. Therefore, the injected formulation consisted of highly condensed microgels, and the administered amount was standardized by injection volume rather than suspension concentration. The mice were allocated into six experimental groups (n = 7 per group): Sham (underwent coronary artery exposure without ligation), MI (permanent LAD ligation), C-S MGs (with HA core), HAPA@C-S MGs, Ab@C-S MGs, and Ab/HAPA@C-S MGs. Five days post-treatment, blood samples were collected via retro-orbital venous plexus puncture using heparinized capillary tubes under isoflurane anesthesia. The collected blood was transferred to serum separation tubes and allowed to clot at 37 °C for 30 min, followed by centrifugation at 3000 g for 15 min at 4 °C. The supernatant serum was carefully aliquoted and stored at −80 °C for subsequent cytokine analysis. Immediately following blood collection, the infarcted hearts were harvested for further analysis. For long-term studies in vivo, male Sprague-Dawley (SD) rats (200 ± 20 g; n = 42; supplied by Hangzhou Medical College) were used. The animals were anesthetized via intraperitoneal injection of 1% pentobarbital (1.7 mL). Following MI induction as aforementioned, 50 μL of microgels were administered at four sites within the infarcted area using an insulin syringe. The rats were randomly allocated to six experimental groups (n = 7 per group), and the experimental groups were established following the same grouping scheme used in the mice experiments. Post-procedural closure involved suturing both thoracic and cutaneous layers with a silk thread. All the animal experimental procedures were conducted in compliance with protocols approved by Zhejiang Center of Laboratory Animals under the guideline of Institutional Animal Care and Use Committee (ZJCLA-IACUC-20011084). PA test via LC-MS PA levels in myocardial infarct tissues were quantified by liquid chromatography-mass spectrometry (LC-MS) following 3-nitrophenylhydrazine (3-NPH) derivatization [51]. Briefly, infarcted myocardial tissues were harvested, rinsed with ice-cold PBS, blotted dried, and accurately weighed. Samples were homogenized in ice-cold methanol/water (80:20, v/v) at a ratio of 1:10 (w/v), followed by sonication in an ice bath for 10 min. The homogenates were centrifuged at 12,000 rpm for 10 min at 4 °C, and the supernatants were collected for derivatization. In brief, 40 μL of tissue supernatant was mixed with 20 μL of freshly prepared 200 mM 3-NPH solution and 20 μL of 120 mM EDC solution containing 6% pyridine, both prepared in 50% aqueous acetonitrile. The reaction was carried out at 40 °C for 30 min. After derivatization, the reaction mixture was diluted to a final volume of 2 mL with 10% aqueous acetonitrile. Subsequently, a 50 μL aliquot was mixed with an equal volume of internal standard solution, and a 10 μL aliquot was injected for LC-MS analysis. LC-MS analysis was performed using a liquid chromatography system coupled with a mass spectrometer equipped with an electrospray ionization (ESI) source (Qtrap6500+, SCIEX, USA). Chromatographic separation was achieved on an AQ-C18 column under gradient elution conditions. The derivatized PA was detected based on its characteristic mass transition. Quantification was carried out using external calibration curves constructed from serially diluted PA standards subjected to identical derivatization and analytical procedures. Echocardiography The cardiac functional recovery in rats was longitudinally assessed by echocardiography at 28 d post-operation using the VEVO2100 ultrasound system (VisualSonics, Canada) under isoflurane anesthesia. The M-mode measurements from parasternal long-axis views at the papillary muscle level were obtained to evaluate left ventricular dimensions. Comprehensive functional analysis quantified ejection fraction (LVEF), fractional shortening (LVFS), end-diastolic volume (LVEDV) and end-systolic volume (LVESV) of left ventricular, providing a complete hemodynamic and structural assessment of post-infarction cardiac recovery. Immunohistochemistry and immunofluorescence staining The mice were euthanized humanely 3 d and 5 d post-MI, and their excised hearts were thoroughly rinsed before immersion in 5 mL of 10% KCl followed by 5 mL PBS. Following cardiac dilation and blood removal, the tissues were fixed in 4% paraformaldehyde overnight. Subsequent processing included paraffin embedding, sectioning, and immunofluorescence staining. Immunofluorescence analyses were performed on dewaxed sections after antigen retrieval, employing specific markers: TUNEL (Beyotime Biotechnology, China) combined with cTnT (cardiomyocyte apoptosis marker; ab8295, Abcam, UK), CCL17 and carboxylesterase 1 (CES1, A01741-1, Boster Biological Technology, China), CD86 (M1 macrophage marker; Boster Biological Technology, China), CD206 (M2 macrophage marker, ab64693, Abcam, UK), IL-17 (Th17 cell marker; M00421-2, Boster Biological Technology, China) and Foxp3 (Tregs transcription factor; ab215206, Abcam, UK). Twenty-eight days post-MI induction, the rats were euthanized to harvest their hearts, which were then sequentially immersed in 10% KCl and PBS for tissue expansion and blood clearance. After apical resection, the ventricular tip was cryopreserved at −80 °C, while the remaining infarcted tissue was fixed in 4% paraformaldehyde (10 mL) for paraffin embedding and sectioning. The sections were stained with Masson's trichrome (Solebo, China) to quantify fibrosis (blue: collagen, red: viable myocardium) as percentage of left ventricular area, with complementary H&E staining revealing infarct pathology. For immunofluorescence staining, the dewaxed sections underwent antigen retrieval before incubation with Cx43 (ab11370, Abcam) for electromechanical coupling, vascular markers α-SMA (ab7817, Abcam) and CD31 (ab182981, Abcam), and WGA (W32466, Invitrogen) for membrane delineation, with imaging performed on an Olympus VS200 slide scanner (Japan). The quantification was performed by calculating the ratio (positive signal area/total infarct area) × 100%. Transcriptomic sequencing analysis Apical myocardial tissues from rats at day 5 post-treatment were collected and immediately stored at −80 °C. Total RNA was extracted from each group using an RNA purification kit. The concentration, purity, and integrity of the isolated RNA were assessed prior to mRNA enrichment. Following mRNA enrichment and reverse transcription, the resulting cDNA was collected, and sequencing libraries were constructed. Gene expression profiles of all treatment groups were compared with those of the MI group. Genes meeting the criteria of |log2FC| ≥ 2.0 and p < 0.05 were identified and ranked, with the top 20 upregulated and top 20 downregulated genes selected for targeted library construction. Subsequent analyses included volcano plot visualization and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway annotation for functional enrichment and biological interpretation. Sequencing was performed on the NovaSeq X Plus (Illumina, USA) or DNBSEQ (MGI, China) platform. Statistics and reproducibility All statistical analyses were performed using GraphPad Prism software (USA). Unless otherwise specified, all experimental data are presented as mean ± standard deviation. One-way analysis of variance (one-way ANOVA) was used for comparisons among multiple groups, followed by Tukey's post hoc multiple comparison test when significant differences were identified. The statistical significance threshold was set at p < 0.05. All experiments in vitro and in vivo were conducted with at least three independent biological replicates to ensure the reliability and reproducibility of the results. Data availability statement The raw/processed data can be requested from the authors. Ethics approval and Consent to participate All the animal experiments in this study were conducted in strict accordance with the guidelines and regulations for the care and use of laboratory animals, and were approved by the Laboratory Animal Welfare and Ethics Review Committee of Zhejiang University (approval number: ZJU20241137), and the Institutional Animal Care and Use Committee of Hangzhou Medical College (approval code: ZJCLA-IACUC-20011085). The experimental protocols were designed to minimize animal suffering and adhere to the principles of the 3Rs (Replacement, Reduction, and Refinement). CRediT authorship contribution statement Liang Song: Conceptualization, Data curation, Formal analysis, Investigation, Methodology, Validation, Writing – original draft, Writing – review & editing. Yongyuan Kang: Data curation, Formal analysis, Investigation, Methodology. Pai Peng: Data curation, Investigation, Methodology. Qiaoxuan Wang: Data curation, Investigation, Methodology. Shuqin Wang: Investigation, Methodology. Liyin Shen: Data curation, Investigation. Jinyue Zhang: Data curation, Methodology. Yang Zhu: Conceptualization, Project administration, Supervision, Writing – review & editing. Changyou Gao: Conceptualization, Funding acquisition, Project administration, Resources, Supervision, Writing – review & editing. Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.